Status check: Bridge copays are excluded from every Part D affordability mechanism

Medicare beneficiaries who get Wegovy, Zepbound KwikPen or Foundayo through the Medicare GLP-1 Bridge pay a flat $50 a month for the drug ^[1]. But because CMS built the Bridge as a demonstration that sits outside the Part D benefit, that money is walled off from the cost-sharing protections built into Part D drug coverage.

CMS states plainly that "the Medicare GLP-1 Bridge will operate outside of the Medicare Part D benefit's coverage and payment flow," and that Part D sponsors carry no risk for the drugs furnished through it and do not have to opt in ^[1]. The agency also notes the Bridge is a Section 402 demonstration and "does not constitute a Medicare Part D plan offering prescription drug coverage," directing beneficiaries who need drug coverage to call 1-800-MEDICARE or their State Health Insurance Assistance Program ^[1].

What "outside Part D" means in practice

Spending that flows through a Part D plan normally does two jobs: it pays for the drug, and it moves you through your plan's deductible and toward the annual out-of-pocket limit, after which covered drugs cost nothing for the rest of the year. Bridge copays do not flow through a Part D plan at all. Claims go to a separate Bank Identification Number and Processor Control Number set up specifically for the Bridge (028918 MEDDGLP1BR), and are adjudicated by a central processor — Humana, the current administrator of the Limited Income Newly Eligible Transition (LI NET) program ^[1].

CMS adds that the Bridge "will be the primary payer for products covered under the Medicare GLP-1 Bridge and will not coordinate benefits with other payers," and that "coupons and discount programs may not be applied to Medicare GLP-1 Bridge claims" ^[1]. The processor also will not accept paper claims or direct member reimbursements ^[1].

The arithmetic is simple. At $50 per fill ^[1], and with the Bridge allowing only a single monthly supply of 28 or 30 days per fill — no 60- or 90-day fills, no partial fills ^[1] — twelve months of continuous treatment comes to $600.

One caution on numbers: the CMS pharmacy guidance reviewed here confirms the $50 copay and the outside-Part D design ^[1], but it does not spell out the 2026 Part D deductible, the exact dollar figure for the annual out-of-pocket cap, or how Extra Help (the low-income subsidy) and the Medicare Prescription Payment Plan interact with Bridge claims. Those details are not addressed in these sources, and beneficiaries who want a definitive answer for their own plan will need it from CMS or their plan.

Why it matters for patients

For someone taking a GLP-1 for weight management plus several other prescriptions, the practical effect is that the $600 in annual Bridge copays does nothing to speed up reaching the Part D out-of-pocket ceiling on those other drugs. It is a separate bill running alongside the Part D bill.

The design also creates a one-way door. CMS warns that if a beneficiary gets a Bridge prior authorization and fills through the Bridge, but later fills a GLP-1 prescription through their Part D plan, they are no longer eligible for the Bridge, and the pharmacy will get a rejection for ineligibility due to prior Part D use ^[1]. And people with type 2 diabetes, moderate to severe obstructive sleep apnea, or noncirrhotic MASH are ineligible for the Bridge because those indications are already covered under Part D — where the spending does count ^[1].

What happens next

The Bridge runs from July 1, 2026 through December 31, 2027, and prior authorization approvals are valid through December 31, 2027, with decisions communicated to prescriber and patient within 72 hours of submission ^[1]. CMS says the product list may be updated over the course of the demonstration; it was already expanded on April 6, 2026 to add Foundayo and to clarify that only the Zepbound KwikPen formulation is included ^[1]. Whether CMS will change how Bridge spending is treated is not stated in these sources.

Broader coverage remains thin outside Medicare: one analysis of 2026 plans cited by healthinsurance.org found only 26 of 300 carriers nationwide covering GLP-1s for obesity, most limiting it to a BMI of at least 40 ^[2].